Literature DB >> 16645322

Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes.

Kazuhiko Hanada1, Rie Ogawa, Kishin Son, Yuuki Sasaki, Akashi Kikkawa, Shiho Ichihara, Hiroyasu Ogata.   

Abstract

BACKGROUND: Alterations of hepatic drug metabolism in patients with renal failure are poorly understood. In this study, the effects of uremic substances that can be removed by hemodialysis on in vitrohepatic drug metabolism were studied using human liver microsomes and hepatocytes.
METHODS: The metabolism of various compounds that undergo oxidation and glucuronidation in the liver was studied using human liver microsomes and hepatocytes in the presence of 11 uremic substances removable by hemodialysis.
RESULTS: The formation of resorufin from ethoxyresorufin was inhibited by 3-indoxylsulfate and 3-indoleacetic acid. The formation of 6beta-hydroxytestosterone from testosterone was inhibited only by 3-indoxylsulfate. These uremic substances reduced the maximum metabolic rate but not the affinity, suggesting that the inhibitory mechanism was noncompetitive. The inhibition of formation of resorufin and 6beta-hydroxytestosterone by 3-indoxylsulfate was also observed in human hepatocytes. The elimination of nicardipine in liver microsomes was decreased significantly in the presence of 3-indoxylsulfate and 3-indoleacetic acid.
CONCLUSION: The hepatic metabolism of certain drugs may be inhibited directly by uremic substances such as 3-indoxylsulfate that accumulate in the plasma in patients with chronic renal failure. Copyright 2006 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16645322     DOI: 10.1159/000092919

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  8 in total

Review 1.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

2.  Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.

Authors:  Yosuke Suzuki; Hiroki Itoh; Fuminori Sato; Kanako Kawasaki; Yukie Sato; Takashi Fujioka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

Review 3.  Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.

Authors:  Alexander J Prokopienko; Thomas D Nolin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-09-20       Impact factor: 5.045

4.  CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.

Authors:  Yosuke Suzuki; Takashi Fujioka; Fuminori Sato; Kunihiro Matsumoto; Nanako Muraya; Ryota Tanaka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino; Hiroki Itoh
Journal:  Br J Clin Pharmacol       Date:  2015-10-03       Impact factor: 4.335

5.  The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.

Authors:  Mindy He Magee; Bonnie Shaddinger; David Collins; Shabana Siddiqi; Joseph Soffer
Journal:  Br J Clin Pharmacol       Date:  2015-07-06       Impact factor: 4.335

6.  The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats.

Authors:  Andrew S Kucey; Thomas J Velenosi; Nicholas C Tonial; Alvin Tieu; Adrien A E RaoPeters; Brad L Urquhart
Journal:  Pharmacol Res Perspect       Date:  2019-04-26

7.  Response to "iPTH is not a significant factor influencing the tacrolimus C/D ratio".

Authors:  Ryota Tanaka; Yosuke Suzuki; Hiroshi Watanabe; Takashi Fujioka; Kenshiro Hirata; Toshitaka Shin; Tadasuke Ando; Hiroyuki Ono; Ryosuke Tatsuta; Hiromitsu Mimata; Toru Maruyama; Hiroki Itoh
Journal:  Clin Transl Sci       Date:  2022-02-19       Impact factor: 4.689

8.  Assessment of Hepatic Cytochrome P450 3A Activity Using Metabolic Markers in Patients with Renal Impairment.

Authors:  Andrew HyoungJin Kim; Sumin Yoon; Yujin Lee; Jieon Lee; Eunjin Bae; Hajeong Lee; Dong Ki Kim; SeungHwan Lee; Kyung-Sang Yu; In-Jin Jang; Joo-Youn Cho
Journal:  J Korean Med Sci       Date:  2018-10-31       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.